PT - JOURNAL ARTICLE AU - Hermann, Bertrand AU - Benghanem, Sarah AU - Pruvost-Robieux, Estelle AU - Sharshar, Tarek AU - Gavaret, Martine AU - Cariou, Alain AU - Diehl, Jean-Luc AU - Candia-Rivera, Diego TI - Brain-heart interactions are associated with mortality and acute encephalopathy in ICU patients with severe COVID-19 AID - 10.1101/2024.10.01.24314706 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.01.24314706 4099 - http://medrxiv.org/content/early/2024/10/01/2024.10.01.24314706.short 4100 - http://medrxiv.org/content/early/2024/10/01/2024.10.01.24314706.full AB - Objective Research in critical care has revealed the significance of autonomic dysfunctions, and more recently of brain-heart interactions, as valuable biomarkers for evaluating patients’ physiological status. These biomarkers provide insights into consciousness levels, severity, and outcomes. This study aims to determine the potential of these biomarkers in predicting the mortality and neurological outcome of severe COVID-19 patients.Methods We examined severe COVID-19 patients who required mechanical ventilation and observed them both during sedation and after sedation cessation. Standard EEG and ECG recordings were conducted at bedside, from which 5 minutes of continuous data were analyzed. Using a synthetic data generation model, we evaluated bidirectional brain-heart interactions from EEG power and heartbeat dynamics series.Results Our findings indicate that brain-heart interactions, especially involving cardiac parasympathetic activity, can provide information about patients’ severity. We observed correlations with acute encephalopathy duration (coma and delirium), particularly evident in top-down markers (from brain to heart) while bottom-up signaling (from heart to brain) correlated with ICU mortality. Additionally, we noted stronger modulation of brain-heart interactions in milder patients when comparing sedation versus non-sedation conditions, compared to those in more severe states.Conclusions Our results imply that autonomic dysfunctions, as measured through brain-heart interactions, can track the pathophysiology of comatose states following COVID-19 infection.Significance These findings highlight the potential of brain-heart interactions as an integrated marker for autonomic function in critical care, offering a more accurate assessment of patient severity and outcomes compared to isolated cardiac or brain measures.Highlights- Brain-heart interactions provide valuable insights into patient severity and neurological outcomes in severe COVID-19 pneumonia.- Brain-to-heart markers correlate with acute encephalopathy duration, while heart-to-brain signaling predicts ICU mortality.- Brain-heart interactions are modulated differently based on assessment timing and the presence of acute encephalopathy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04527198Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was granted by Comité de Protection des Personnes Ile-de-France II (ID RCB: 2020-01559-30) and the study was a priori registered on clinicaltrials.gouv: NCT04527198. A written informed consent was obtained from each of the patients or their relatives.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsACE2Angiotensin-converting enzyme 2AEAcute encephalopathyARDSAcute respiratory distress syndromeAUCArea under the curveCAMConfusion Assessment MethodCOVID-19Coronavirus disease 2019CPICardiac parasympathetic indexCSICardiac sympathetic indexECGElectrocardiogramEEGElectrocephalogramFOURFull outline of unresponsivenessHRHeart rateHRVHeart rate variabilityICUIntensive care unitSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SOFASequential organ failure assessmentRASSRichmond agitation sedation scale